EZH2 and prostate cancer: Furthermore, the genome-wide analysis of various datasets of primary and metastatic prostate cancers showed that the concurrent EZH2 and TOP2A expression identifies a number of patients with more aggressive disease and overlap with genes involved in mitotic regulation.